J&J Baby-Care Sales Down With Second Talc Cancer Trial Underway
This article was originally published in The Rose Sheet
Executive Summary
A second trial examining an alleged link between perineal use of J&J's talcum-based powder products and ovarian cancer began April 11, following a February jury verdict in the same court that ordered the firm to pay $72m in damages to the family of an ovarian cancer casualty. J&J's baby-care performance weighed on overall results in the firm's first fiscal quarter, while OTC product sales continue to rebound.
You may also be interested in...
J&J Consumer Products Business Steers Toward Acquisitions For Growth
Firm continues to be outspoken about its M&A appetite, recently closing deals for Vogue International and NeoStrata, among others. Neutrogena and Aveeno were top performers for J&J’s Consumer business in the second quarter, the company says.
J&J Talc Verdict Spells Opportunity For Plaintiffs, Talc-Free Powder Market
Johnson & Johnson is working to assure consumers of talc safety following a St. Louis jury verdict ordering the company to pay $72m in damages to the family of a late Alabama woman who attributed her ovarian cancer to perineal use of the company's baby and body powders. Around 1,200 similar cases are pending against the company in Missouri and New Jersey courts.
Cosmetics Industry Awaits FDA’s Allergen List While Working To Inform GMP Rulemaking
The Independent Beauty Association does not yet have insight into what ingredients will be listed in the US FDA’s proposed rulemaking for cosmetic allergen labeling – due by 29 June – but is optimistic the agency will consult industry when it comes to setting the compliance timeline. Meanwhile, industry stakeholders are pushing for international harmonization in the agency’s cosmetic GMPs rulemaking.